Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis: The UC Horizons Project.

dc.contributor.authorGisbert, Javier P
dc.contributor.authorBarreiro-de Acosta, Manuel
dc.contributor.authorEsteve, María
dc.contributor.authorGarcía-Sánchez, Valle
dc.contributor.authorGomollón, Fernando
dc.contributor.authorGuardiola, Jordi
dc.contributor.authorHinojosa, Joaquin
dc.contributor.authorMartín Arranz, Maria-Dolores
dc.contributor.authorMinguez, Miguel
dc.contributor.authorTaxonera, Carlos
dc.contributor.authorVera, Isabel
dc.date.accessioned2025-01-07T13:27:35Z
dc.date.available2025-01-07T13:27:35Z
dc.date.issued2016
dc.description.abstractThere is still uncertainty about what constitutes the best therapeutic practice in ulcerative colitis (UC). The purpose of the "UC Horizons Project" was to raise a series of questions regarding the management of UC to provide responses based on the best scientific evidence available. The 11 members of the scientific committee prepared draft answers to the 10 questions from available evidence after a literature search. A total of 48 Spanish gastroenterology specialists nationwide participated in the project. The national meeting discussed the 10 issues in working groups and reached consensus regarding the recommendations by anonymous, interactive vote following the Delphi methodology. Final answers were developed, based on evidence and clinical experience of the participants. All the recommendations achieved a high level of agreement in the plenary vote, although the quality of the evidence was markedly heterogeneous. The lowest percentage of agreement corresponded to the questions with the weakest level of evidence, highlighting the necessity of conducting further studies in these areas. The recommendations focused on (1) aminosalicylates therapy (regarding dose and appropriateness of coadministration with thiopurines), (2) corticosteroid therapy (regarding dose and route of administration), (3) thiopurine treatment (regarding indications and possibility of withdrawal), (4) anti-tumor necrosis factor therapy (regarding appropriateness of combination with thiopurines, intensification, or discontinuation of treatment), and (5) colorectal cancer (regarding risk and time trends). The UC Horizons Project raised a series of eminently practical questions about the management of UC and provided responses based on the best scientific evidence available.
dc.identifier.doi10.1097/MIB.0000000000000617
dc.identifier.essn1536-4844
dc.identifier.pmid26529561
dc.identifier.unpaywallURLhttps://academic.oup.com/ibdjournal/article-pdf/22/3/583/23403107/ibd0583.pdf
dc.identifier.urihttps://hdl.handle.net/10668/25530
dc.issue.number3
dc.journal.titleInflammatory bowel diseases
dc.journal.titleabbreviationInflamm Bowel Dis
dc.language.isoen
dc.organizationSAS - Hospital Universitario Reina Sofía
dc.organizationInstituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)
dc.page.number583-98
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rights.accessRightsopen access
dc.subject.meshAttitude of Health Personnel
dc.subject.meshColitis, Ulcerative
dc.subject.meshConsensus
dc.subject.meshDisease Management
dc.subject.meshGastroenterology
dc.subject.meshHumans
dc.subject.meshPhysicians
dc.subject.meshPractice Guidelines as Topic
dc.subject.meshRemission Induction
dc.subject.meshSurveys and Questionnaires
dc.titlePhysician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis: The UC Horizons Project.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number22

Files